Precision Medicine in Oncology® | Specialty

ASCO Backs EGFR Testing for Lung Cancer Patients

April 15th 2011

The chorus of support is growing among oncology experts for routine genetic testing of tumors from patients with advanced non-small cell lung cancer

Biomarker Test Shows Promise in Diagnoses

April 6th 2011

A biomarker test for DNA methylation identified 22 gene sites able to differentiate between melanoma and nonmelanoma lesions

Federal Spending on Research Into Kidney Cancer Is Rising

April 4th 2011

The use of microRNAs and proteomics-based approaches for early detection are among the foremost research priorities of the National Cancer Institute

Dr. Gomella on Jefferson's Multidisciplinary Cancer Center

March 31st 2011

Landmark Genome Analysis to Drive Multiple Myeloma Research

March 28th 2011

Genome sequencing may help researchers understand the pathogenesis of this cancer, which despite exhaustive research, is only partially understood

Dr. Kris Discusses EGFR Mutation Testing

March 21st 2011

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York Discusses EGFR Mutation Testing

Dr. Alter on Trials and Ongoing Research in Kidney Cancer

March 21st 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Dr. Pearlstone on Ongoing Research in Breast Cancer

March 16th 2011

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.

Announcing a New Partnership and an Opportunity for Growth

March 16th 2011

The John Theurer Cancer Center is proud to be partnering with Intellisphere to advance this mission by overseeing editorial content development and helping to provide in-depth content, new learning opportunities, and bestpractice approaches to cancer care.

Dr. Pecora on his Personal Involvement in Research

March 15th 2011

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

Dr. Alter Discusses Research at JTCC

March 14th 2011

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Dr. Siegel Discusses the New John Theurer Cancer Center

March 14th 2011

David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.

Advice for Newly Diagnosed Kidney Cancer Patients

March 14th 2011

Ana M. Molina, MD, Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Gives Advice for Newly Diagnosed Kidney Cancer Patients

What Separates MSKCC From Cancer Centers Worldwide

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Discusses what Separates MSKCC From Other Top Cancer Centers Worldwide

Dr. Pearlstone on Genomics and Personalized Medicine

March 10th 2011

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Genomics and Personalized Medicine

Biomarkers in Ovarian Cancer: Early Detection and Chemoresistance

March 4th 2011

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

South Florida's Sylvester Comprehensive Cancer Center: Hitting Its Stride

March 2nd 2011

The Sylvester Comprehensive Cancer Center (SCCC), part of the University of Miami Health System, first opened its doors in 1992. Over the years, the SCCC has become the hub of cancer research in the region.

Yale Cancer Center: Innovation Abounds in New Facilities

March 2nd 2011

In 1974 the National Cancer Institute designated Yale Cancer Center as one of the country's inaugural comprehensive cancer centers.

Clinical Trial Reports: September 2007

July 8th 2010

The Clinical Trials reported in this issue include: PHASE IV: Obesity a Major Risk Factor for Multiple Myeloma PHASE III: 1) Long-Term Safety of Adjuvant Trastuzumab (Herceptin) 2) Bevacizumab (Avastin) Helps Slow Tumor Growth in Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer 3) Addition of Bevacizumab To Interferon Alfa 2a Nearly Doubles Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer, and more

Clinical Trial Reports: July/August 2007

July 7th 2010

Among the Clinical Trials reported in this issue are: PHASE III: 1) More Positive News in GPC Biotech's Trial With Satraplatin 2) Sanofi-Aventis Presents Positive Results in Three Oncology Programs 3) Imatinib (Gleevec) After GIST Surgery Achieves Significant Survival Benefit, and more